PT  - JOURNAL ARTICLE
AU  - KW Leong
AU  - TL Law
AU  - AS Saiful
AU  - Kang
AU  - Woo
AU  - Chow
AU  - ZL Yong
TI  - Excellent negative predictive value (99.8%) of two rapid molecular COVID-19 tests compared to conventional RT-PCR for SARS-CoV-2 (COVID-19) in 2,011 tests performed in a single centre
AID  - 10.1101/2021.06.20.21258392
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.06.20.21258392
4099  - http://medrxiv.org/content/early/2021/06/21/2021.06.20.21258392.short
4100  - http://medrxiv.org/content/early/2021/06/21/2021.06.20.21258392.full
AB  - Conventional Reverse Transcription Polymerase Chain Reaction (RT-PCR) remains the gold standard for testing SARS-CoV-2. Since their availability, two rapid molecular COVID-19 tests were performed in parallel with RT-PCR in all urgent and emergency admissions, as the negative predictive value was not yet ascertained. In this study, we present the data of 2,011 test results using either ID Now COVID-19 (Abbott) (Abbott ID NOW) or Xpert Xpress SARS-CoV-2 (Cepheid) (GeneXpert) tests comparing to conventional RT-PCR results. The negative predictive value is 99.8%(3 false negatives out of 1,964 tests) using a cut-off CT value of 40. Using a cut-off of RT-PCR CT value of 30 (predicting infectivity), the negative predictive value is reduced to 99.9% (1 out of 1,964 tests). With these results, we feel confident to recommend the immediate use of the rapid PCR tests alone and to use conventional RT-PCR for confirmation testing after.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding was necessaryAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Ethics Committee of Gleneagles Hospital Penang has reviewed this retrospective quality control study and do not fined any ethical issues. The committee has granted approval for this study. The committee consists of Chairman: Dato Dr Lai Yoon Kee, PIC Gleneagles Hospital Penang Deputy Chairman: Dr Goh Kay Wah, Medical Director, Gleneagles Hospital Penang Members: Mr Ivan Loh, CEO; Dr Rajesh Shah, Head of Medical Specialties; Dr Hafiz Law, Consultant Cardiothoracic Surgeon; Mr Guansekaran, Consultant Neurosurgeon; Mr Palaniappan, Consultant ENT Surgeon; Dato Dr Adel Zaatar, Consultant Clinical Oncologist. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are kept in the laboratory computer system.